RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

Methods83 patients with hepatocellular carcinoma (HCC) admitted to the interventional oncology department were randomly divided into two groups. Apatinib and camrelizumab were administered to 42 patients in group A, whereas sorafenib was administered to 41 patients in group B for three months. The c...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Qing Yang, Gengyu Li, Xiaoqiu Wu, Haiying Lin, Wanrui Wu, Xiangpang Xie, Yu Zhu, Wei Cai, Changsheng Shi, Shengye Zhuo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Subjects:	Apatinib camrelizumab hepatocellular carcinoma advanced stage tumor markers
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1136366/full